A trial to investigate the results of intravitreal bevacizumab for choroidal neovascularization (CNV) secondary to angioid streaks and to assess the factors influencing disease progression
Latest Information Update: 31 May 2016
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Angioid streaks; Choroidal neovascularisation
- Focus Adverse reactions; Therapeutic Use
- 31 May 2016 New trial record